Bayer results boosted by strong pharma performance

28 February 2014

Germany’s Bayer (BAYN: DE) this morning posted financial results for 2013, showing that group sales for the year reached 40.16 billion ($54.05 billion), plus 1.0% ex & portfolio adj: 5.1%. Earnings before interest and tax (EBIT) advanced 25.6% to 4.93 billion euros.

Earnings before interest, tax, depreciation and amortization (EBITDA) and special items were up 1.5% to 8.40 billion euros. Net income increased 32.7% to 3.19 billion euros, with core earnings per share up 5.8% to 5.61 euros. Bayer’s shares gained 1% to 100.80 euros in early trading.

Fourth-quarter sales edged 0.3% higher to 9.86 billion euros, with healthcare segment sales up 0.4% to 4.92 billion. Fourth-quarter earnings EBITDA and special items declined about 3.1% to 1.77 billion euros, falling short of the 1.92 billion-euro average estimate of 12 analysts surveyed by Bloomberg.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK